Introduction
Labor and delivery can rapidly change from a normal to a potentially high risk situation. Accordingly, careful monitoring of mother and fetus has become the standard of care. Continuous electronic "fetal" monitoring (EFM) of fetal heart rates and uterine contractions is used almost universally in the United States. EFM information is sensitive to the possibility of dangerous deficits in fetal oxygen supply. However EFM data yields about 50 to 60% false positive "diagnoses" of significant fetal hypoxia (1) and may not detect up to 15-20% of true hypoxia. The most specific index of prolonged and potentially dangerous insufficient oxygen delivery is fetal blood pH (BpH); measured from drops of blood carefully collected from a small incision on the fetal scalp. The combination of BpH and EFM data reduces the incidence of false positives, while also improving detection of true problems. These combined data can be used to substantially reduce the Cesarean section rate for fetal distress (1) (2) (3) (4) . It is estimated that BpH information may be clinically important in up to 25% of patients (3, 5) .
However, BpH data is not commonly available because of the skills, time, inconvenience and laboratory facilities needed to obtain reliable measurements. Further one BpH measure is insufficient to determine the trend of fetal pH (5) . Finally, the tools and methods are primitive and there is some fetal risk (2) . For all these reasons, and despite its potential value, BpH has not become the standard of practice in the United States.
The information inherent in the BpH measurement could be made widely available if there were a convenient safe probe to continuously monitor intrapartum fetal pH. This paper describes an investigational fetal pH probe designed to be safe and convenient. At this time, the goal of the device is to provide reliable fetal pH status and trend data for use as an adjunct to EFM and BpH data for clinical care.
Historical Perspective
The first fetal pH probe to undergo widespread clinical trials was the Stamm tissue pH (tpH) probe, designed for monitoring the pH of the subcutaneous fluid in the fetal scalp (6, 7) . Several studies demonstrated the validity of the basic concept of Stamm: human fetal acid-base balance can be monitored and evaluated by continuous monitoring of the scalp tpH (8) (9) (10) (11) (12) . Clinical utility included a reduction in operative intervention for deliveries (9) . However the Stamm device required sterile assembly and charging with sterile reference electrolyte a scalp incision for probe insertion and mastery of a difficult technique for apply and fixing the probe to the fetal scalp. The system was found to be impractical and the technique unreliable for routine clinical use.
In order to help to make these potentially valuable fetal tpH data generally available the authors and clinician investigators are evaluating a system and tpH probe designed to be convenient, safe, and reliable for continuous monitoring of fetal pH status. Fiberoptic, electro-optic, microprocessor and analytic chemistry technologies were integrated to produce a feasibility system designed for evaluation of continuous clinical monitoring of the fetal pH status during labor: The OBpH™ 1000 System. Using the experience gained in monitoring over 300 patients between late 1983 through mid 1985, a total system designed to be convenient and simple for routine use by the clinician was designed and built. The latter system, the OBpH 1500, is in evaluation at this time. This paper describes the OBpH 1500 system and outlines clinical results from the earlier OBpH 1000 system, which used the same tpH probe.
Because this is an unreleased FDA Class III Investigational Devise in evaluation for regulatory purposes, International Biomedics can make no claims regarding safety, effectiveness or utility of the system. Further, it should be understood the device is designed as an adjunct to EFM and fetal scalp blood sampling, not as a total replacement for either measurement. (1987) 
System Description
The OBpH 1500 System includes a fetal scalp pH ECG probe, an applicator tool, an electro-optic Interface module, an off-line Calibration chamber, and a fetal monitor for data display ( Figures  1,2) . The probe is a 22 gauge spiral ECG electrode which includes a fiberoptic-based pH sensor (Fig. 3,4) . The probe is applied to the fetal scalp with the same general technique used for spiral ECG electrodes. When properly placed within the scalp, the pH sensor is within the subcutaneous fluid and the probe detects both subcutaneous fluid (tissue) pH and fetal ECG.
The probe is supplied in a sterile pack, with the tpH sensor within pH 7.00 buffer. After insertion of the probe pack and connector into the Interface, and insertion of the Interface into the Calibrator, the probe is automatically warmed, stabilized, stored and calibrated within the sterile pack. PH 7.36 Calibration is begun by depressing a sealed plunger through the cover of the sterile probe pack. The Calibrator checks for problems, confirms the reliability of the calibration, and the probe is ready for use within about 15 minutes. The calibrated probe can be used with confidence for up to 8 hours. 
Preparation of the Model 1500 OBpH System
The OBpH 1500 Interface mates with either the calibrator or the monitor. It acquires and retains the probe calibration data, allowing the patient to be disconnected from and reconnected to any appropriate FetaScan 1500 monitor by disconnecting and reconnecting the interface, without disconnecting the probe.
The OBpH probe is in a sterile sealed package and it can be fully calibrated in this package without impairing sterility. Once calibrated, it can be placed at the bedside ready for use. The semiautomatic Calibrator holds 4 probe-interface packages ready for final calibration and use.
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Figure 3
Drawing of the tpH probe in situ in the fetal scalp, with the applicator tool attached. The spiral forms one pole of the EGG electrode and the hub is the other. The tpH sensor window is just below the skin surface, facing into the subcutaneous tissue in order to measure the pH of the interstitial fluid. 
Fiberoptic pH Probe Design

Figure 4 Principle of Operation of the Fiberoptic pH Probe
The above assembly is inserted into the solution to be measured. Protons (H+) diffuse freely through the dialysis hollow fiber into the dye column. The column contains a reversible pH-sensitive non-toxic dye covalently bound to a gel matrix (to prevent escape of dye). A fiberoptic fiber guides light to the dye, and directs reflected light to the instrument. There the green reflectance, the red reflectance, and the current with no light (dark current) are measured. The absorbance of green light by the dye is proportional to the pH in the range of interest, while red absorbance is not affected by pH. The red relectance is used as a reference signal.
The Interface module, with probe still attached, is then moved to the bedside. The pack is opened and the probe applied to the fetal scalp. The interface module is then attached to the FetaScan monitor, which automatically acquires and merges the tpH with the monitoring data on its strip chart and the video display, and continuously checks the validity of the optical data in order to flag problems (Fig. 5) .
ILLUSTRATIVE DATA INTRAPARTUM FETAL tpH MONITORING
Figure 5 Chart Display of Simultaneous Fetal Monitor and OBpH Data
The fetal heart rate (FHR) demonstrates significant decelerations concordant with uterine activity (UA). The U A channel includes a tpH scale which ranges from pH 7.00 (bottom of record) to 7.40 (top of UA channel). The tpH is displayed as a linear graph on the UA channel, and it is updated every 20 seconds with the average tpH for the past 20 seconds. Each minute the average tpH is printed on the FHR channel (vertical printed statements). The FetaScan video displays the 20 second updated tpH value.
In-Vitro Performance of the OBpH System
In order to be useful as a trend monitor the OBpH system must resolve changes in pH at least as well as the current technology: the BpH. The 95% confidence interval (ci) of the BpH measurement is reported to be 0.06 pH or greater, with a non-Gaussian distribution (13, 14) . In-vitro studies of the OBpH probe demonstrate the 95% ci is 0.03 pH (Fig. 6) . The absolute accuracy is within ±0.05 pH of a blood gas analyzer, which is also within the 95% confidence limits of blood measurement. Published data (8, 15) show the high degree of correlation R>0.9 with in-vitro measurements of human fetal and adult blood. 
Figure 6 Reproducibility of pH Measurement with a Single Fiberoptic tpH Probe
The OBpH 1500 data is compared to blood gas analyzer pH (BGpH) at eight data points. The probe is first calibrated and then immersed in buffers of six other pH, and it is recycled through all eight pH at least twice. The probe must reproduce each data point within a bandwidth of ±0.03pH.
Clinical Investigational Plan
The feasibility model 1000 OBpH system was used in eight U.S. centers to monitor over 300 term or post-date high risk patients where BpH was indicated. The BpH was used to document th£ reliability of the current technology, the BpH, in following trends and to validate the reliability and the OBpH monitor in following trends of fetal pH status and in classifying fetal pH status as normal vs. notnormal.
The study goals: 1. Document the incidence of fetal or maternal problems caused by the OBpH in order to compare its safety with current technology. 2. Measure the inherent reliability of the tpH data for monitoring fetal pH status. "Inherent" means both the BpH and the OBpH data were unflawed or untainted, according to the investigator's report and an independent non-clinician reviewer at International Biomedics. 3. Document the perceived added value and clinical relevance of the OBpH monitoring data, when used as an adjunct to EFM and BpH measurements.
Clinical Study Methods
• Subject selection criteria: -Term or post-date patients in labor with vertex fetal presentation, and sufficient dilation and station to properly place the probe.
-A documented indication for fetal scalp blood sampling for pH measurements.
-No contraindications to fetal scalp blood sampling for pH measurements.
-Informed consent given.
• Study Population: (Table I) • "Qualified Data Analysis" was used to measure the intrinsic reliability of the OBpH to monitor (correlate with) fetal CpH measurements, given no experimental flaws or "tainted data" and given the inherent variability of the CpH data. The correlation of replicate fetal CpH measures was determined in order to quantify the reliability of the current technology. Next, the tpH-CpH correlation data were calculated for those data points with replicate CpH, and then for all qualified sets of related tpH-CpH (Table II) .
• "Physiological Data Analysis" was used to measure the clinical reliability of OBpH in trending fetal pH status, as measured by the correlation coefficient, given no obvious problems known to the investigator and pH values in the system operating range 7.09-7.44. (Tables II & III) .
• Reliability of classification of fetal CpH by the OBpH data. These data included the predictive value of a normal tpH (7.20-7.44) vs. a normal CpH (7.25+) and the accuracy of both normal and not normal tpH to respectively predict normal & not normal CpH (efficiency of tpH). These data quantified the reliance the clinician can place as the tpH reflecting the CpH status. (Tables II & III) .
• Success in obtaining a reliable OBpH trend record as compared to the success of obtaining reliable CpH measurements was measured. Certain conditions are known to interfere with blood pH and fetal scalp ECG reliability because free access to the scalp is blocked, and these similarly interfere with OBpH probe fixation. The most notable in this study was thick matted fetal hair. Meconium, scalp edema and duration of monitoring or labor did not consistently interfere with OBpH or BpH data.
• The potential clinical relevance of the OBpH data in patient management in addition to the FHR and BpH data was reported on the data forms and tallied. 
Success in Obtaining Fetal pH Data
The clinical experience demonstrated a continuous OBpH monitoring record could be obtained as frequently as a single valid fetal scalp blood pH data point (80%). With the OBpH 1500, the process was perceived to be simpler than obtaining one set of fetal scalp blood pH data point.
Clinical Relevance of the QBpH Data
The OBpH data was perceived as clinically relevant in 65% of these case reports. The most commonly mentioned advantages were:
•Reassurance of fetal pH stability and normalcy, especially despite other changes suggestive of possible fetal deterioration.
(Abnormal FHR, Thick Meconium) This impression was validated by the 100% predictive value of a normal tpH.
•Avoiding extra fetal scalp blood samples.
•Detecting trends in pH before they can be resolved by the blood pH method. (Because of the OBpH self consistency)
•Using the OBpH record as a guide to timing fetal scalp sampling for blood pH. Usually there is no clear-cut indication as to when the pH is changing and may need diagnostic confirmation. The OBpH trend uniquely provides this information.
•Monitoring fetal pH status where it is impractical to obtain timely repetitive blood pH data. This is particularly relevant during stage II of labor, when abnormal heart rate patterns are common.
Discussion and Conclusions
The data demonstrated the OBpH system and the tpH method was inherently capable of reliable monitoring of fetal pH status, albeit with a different absolute value. The inherent consistency of the OBpH was obscured by the variability of the current technology, the BpH, the additional inter-institutional difference in BpH reliability; and possibly by clinical factors such as thick fetal hair. Also, there is an initial learning curve effect. At the start of the program, the correlation coefficient of tpH to OBpH was about 0.6. The last studies revealed correlation coefficients of 0.8 to 0.95 with a few or no tainted data points. Throughout the study, there were no false normal tpH values. When the tpH was 7.25 to 7.44, the unflawed BpH was always in the normal range.
Most clinicians perceived the data from the OBpH system to be clinically relevant, especially in monitoring trends of fetal pH status during worrisome events or events where repetitive timely BpH cannot be obtained. The investigators also immediately perceived the reliability of a normal and stable OBpH record.
To date, the clinical results obtained from the OBpH 1500 system are encouraging with respect to both practicality and reliability of the data.
